Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors [0.03%]
固体瘤患者中BNT162b2抗SARS-CoV-2疫苗免疫原性减弱
J Barrière,E Chamorey,Z Adjtoutah et al.
J Barrière et al.
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial [0.03%]
一项比较truatedin与最佳支持治疗以既往经治的软组织肉瘤患者中的III期随机试验：法国肉瘤组T-SAR试验
A Le Cesne,J-Y Blay,D Cupissol et al.
A Le Cesne et al.
Background: The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). ...
Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs [0.03%]
关于信件“检查点抑制：预防还是促发继发性原发肿瘤？”的回复
P Heudel,S Chabaud,D Perol et al.
P Heudel et al.
Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays [0.03%]
高灵敏度和特异性的双重分子条形码个性化突变检测在早期筛查发现的乳腺癌中的ctDNA阳性率研究
K Page,L J Martinson,R K Hastings et al.
K Page et al.
Practical considerations in screening for genetic alterations in cholangiocarcinoma [0.03%]
胆管癌基因改变筛查实践中的考虑因素
T S Bekaii-Saab,J Bridgewater,N Normanno
T S Bekaii-Saab
Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit of standard chemotherapy for advanced disease. Comprehensive ...
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE [0.03%]
新辅助治疗后HER2阳性乳腺癌残留病残患者中T-DM1与曲妥珠单抗的辅助治疗：KATHERINE研究亚组分析
E P Mamounas,M Untch,M S Mano et al.
E P Mamounas et al.
Background: In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a...
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793) [0.03%]
帕博利珠单抗治疗林奇样和MLH-1甲基化特征的复发微卫星不稳定性高（MSI-H）子宫内膜癌患者的II期评估（NCT02899793）
S Bellone,D M Roque,E R Siegel et al.
S Bellone et al.
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients [0.03%]
接受治疗的癌症患者接种一次SARS-CoV-2信使RNA疫苗后的弱免疫原性
R Palich,M Veyri,S Marot et al.
R Palich et al.
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds [0.03%]
预后不良前列腺癌的治疗选择及效果：并非不可能战胜病魔
D G J Robbrecht,S A J Buck,R de Wit
D G J Robbrecht
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 [0.03%]
对于既往未经治疗的转移性非鳞状NSCLC患者，帕博利珠单抗联合培美曲塞和铂类与安慰剂联合培美曲塞和铂类疗效的对比：KEYNOTE-189研究最终分析结果
D Rodríguez-Abreu,S F Powell,M J Hochmair et al.
D Rodríguez-Abreu et al.
Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival ...